

## Development of anti-PD-L1 x anti-SIRP $\alpha$ bispecific antibody that systemically activates both innate and adaptive anti-tumor immune system

PharmAbcine Inc.



ONCOLOGY	Hit
Product Type	Bispecific antibody
Indication	Solid tumor/Hematologic cancer
Target	Single-regulatory protein $\alpha$ [SIRP $\alpha$ ] and Programmed cell death-ligand 1 [PD-L1]
MoA (Mechanism of Action)	Engage macrophages and cancer cells $\rightarrow$ (1) Inhibit CD47/SIRP $\alpha$ interaction $\rightarrow$ Promote phagocytosis (2) Block PD-1/PD-L1 signaling $\rightarrow$ Promote T cell activity
Competitiveness	Dual targeting of PD-L1 on tumor cells and SIRP $\alpha$ on innate immune cells (e.g., macrophages) acts as a “bispecific innate immune cell engager” and further establishes immunologic synapse, which can potently induce both innate and adaptive immune responses fighting back against cancers.
Development Stage	Hit
Route of Administration	Parenteral-Intravenous